French Pharmaceuticals & Biotech Top Stock Picks from Analysts

Valneva

Market Cap: €511.9m

A specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.

Inventiva

Market Cap: €383.9m

A clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.

Nanobiotix

Market Cap: €235.1m

Operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs.

Genfit

Market Cap: €173.0m

A late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases.

Innate Pharma

Market Cap: €156.7m

Operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.

Cellectis

Market Cap: €141.7m

A clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.

OSE Immunotherapeutics

Market Cap: €128.7m

A clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally.

Transgene

Market Cap: €112.5m

A biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France.

Sensorion

Market Cap: €98.0m

A biotechnology company, develops drug candidates for the treatment of inner ear disorders in France.

Adocia

Market Cap: €90.5m

A clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases.

AB Science

Market Cap: €84.0m

A clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France.

MaaT Pharma

Market Cap: €71.2m

A late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival.

ABIONYX Pharma

Market Cap: €44.9m

A biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases.

Nicox

Market Cap: €23.6m

Operates as an ophthalmology company in France and internationally.

GenSight Biologics

Market Cap: €20.8m

A clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system.

NFL Biosciences

Market Cap: €14.9m

A biotechnology company, engages in the development of natural addiction withdrawal solutions for smokers.

Advicenne

Market Cap: €14.5m

A specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally.

Valbiotis

Market Cap: €13.7m

Engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France.

Predilife

Market Cap: €12.4m

Designs and markets predictive tests for the occurrence of serious illnesses.

Theranexus Société Anonyme

Market Cap: €10.2m

A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.

TME Pharma

Market Cap: €10.1m

A clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany.

Aelis Farma

Market Cap: €9.9m

A clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France.

Oncodesign Precision Medicine Société anonyme

Market Cap: €9.3m

A biopharmaceutical company, engages in the precision medicine business.

PHAXIAM Therapeutics

Market Cap: €1.0m

A biopharmaceutical company, focuses on developing solutions to combat severe and resistant bacterial infections in France and the United States.